Phospho-IR/IGF1R (Tyr1162, Tyr1163) Recombinant Rabbit Monoclonal Antibody (97H9L7), Invitrogen™

Description

• This antibody is predicted to react with bovine, canine, chicken, chimpanzee, equine, mouse, rat, Rhesus monkey , porcine and Xenopus based on sequence homology
• Intact IgG appears on a non-reducing gel as ∽150 kDa band and upon reduction generating a ∽25 kDa light chain band and a ∽50 kDa heavy chain
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• Insulin and Insulin-like Growth Factor receptors are transmembrane tyrosine kinase receptors that play critical roles in development, cell growth and metabolism
• Insulin/Insulin-like growth factor-1 binding to the extracellular domain of IR and IGFR leads to autophosphorylation of the receptor and activation of the intrinsic tyrosine kinase activity, which allows appropriate substrates to be phosphorylated
• Phosphorylation sites that are unique to each receptor presumably play a key role in these signaling differences
• The catalytic loops within the tyrosine kinase domains contain a three tyrosine motif corresponding to Tyr1158, 1162 and 1163 (for the IR) and Tyr1131, 1135 and 1136 (for the IGF1R)
• Autophosphorylation of the tyrosine sites within the activation loop proceeds in a processive manner initiating at the second tyrosine (1162 or 1135), followed by phosphorylation at tyrosines 1158 (IGF-1R tyrosine 1131), 1163 (IGF-1R tyrosine 1136), resulting in the full activation of IR and IGF1R.